Spatial and Temporal Heterogeneity in High-Grade Serous Ovarian Cancer: A Phylogenetic Analysis

Roland F. Schwarz(Helmholtz Association of German Research Centres), James D. Brenton(Cambridge University Hospitals NHS Foundation Trust)

PLoS Medicine

February 24, 2015

10.1371/journal.pmed.1001789

Cited by 416

Related Papers

Rethinking ovarian cancer: recommendations for improving outcomes

|Nature reviews. Cancer|2011|1.5k

Rethinking ovarian cancer II: reducing mortality from high-grade serous ovarian cancer

|Nature reviews. Cancer|2015|1.4k

Weekly dose-dense chemotherapy in first-line epithelial ovarian, fallopian tube, or primary peritoneal carcinoma treatment (ICON8): primary progression free survival analysis results from a GCIG phase 3 randomised controlled trial

|The Lancet|2019|223

ICON8: A GCIG phase III randomised trial evaluating weekly dose- dense chemotherapy integration in first-line epithelial ovarian/fallopian tube/primary peritoneal carcinoma (EOC) treatment: Results of primary progression- free survival (PFS) analysis

|Annals of Oncology|2017|51

Weekly dose-dense chemotherapy in first-line epithelial ovarian, fallopian tube, or primary peritoneal cancer treatment (ICON8): overall survival results from an open-label, randomised, controlled, phase 3 trial

|The Lancet Oncology|2022|45